WuXi Global Forum 2017, now in its fifth year, brings together 1,000 industry leaders to promote new thinking on a global stage as we strive to find transformative models and solutions for patients, at a time when stakes are higher than ever for our industry.
Host: WuXi AppTec
Date and Time: 2:00-7:00 PM Pacific Standard Time, Jan 10, 2017
Venue: Grand Hyatt San Francisco, Grand Ballroom
Ge Li, Chairman, WuXi AppTec Group
The hurdles could not be higher for young companies working on diseases that have taken their toll even amongst the most experienced drug hunters. This panel takes a closer look at three startup all-stars on how they are tackling tough diseases through unique lenses, and launching a new generation of clinical stage programs.
Moderator: David Flores, President and CEO, BioCentury
Ryan Watts, CEO, Denali Therapeutics
Keith Leonard, CEO, Unity Biotechnology
Yujiro Hata, Co-Founder and CEO, IDEAYA Biosciences
This panel asks where the next big things would be in global healthcare innovation, and how VCs are building next generation companies with disruptive technologies, with global ambitions, and beyond industry boundaries.
Moderator: Edward Hu, CFO and CIO, WuXi AppTec
Alexis Borisy, Partner, Third Rock Ventures
Shoucheng Zhang, Professor at Stanford University; Chairman, Danhua Capital
Yibing Wu, Joint Head of Portfolio Strategy & Risk Group and Joint Head of China, Temasek
John Reed and Peter Schultz are no strangers in successfully tackling big questions. In this chat with Gregory Verdine, they share fresh perspectives on effecting transformational changes in their organizations, and on translating science into meaningful difference to patients.
Moderator: Gregory Verdine, Erving Professor of Chemistry, Harvard University; CEO, FogPharma and LifeMine; Partner, WuXi Healthcare Ventures
John Reed, Head of Pharma Research and Early Development (pRED), Roche
Peter Schultz, CEO, The Scripps Research Institute and Calibr
This panel will discuss how sequencing and other molecular tools are being employed for profiling, testing, and diagnostic opportunities enabled by immunooncology, liquid biopsy, combination therapy and others to capture the full potential of personalized medicine.
Moderator: Thomas Caskey, Professor of Baylor College and SVP of Medical Science & Diagnostics, WuXi NextCODE
Ken Drazan, Chief Business Officer, GRAIL
William Morice, Chair, Department of Laboratory Medicine and Pathology, Mayo Clinic; President, Mayo Medical Laboratories
Chad Robins, President and CEO, Adaptive Biotechnologies
From the first 1st-in-class drug developed entirely in China for diabetes, to the largest biotech private financing in China to advance biologics pipeline, to multiple high-flying China oncology deals to enable global development, this panel will showcase three biotech all-stars in the US and China with vast experiences in bringing transformative therapies faster to Chinese patients.
Moderator: Steve Yang, EVP and COO, WuXi AppTec
Lonnie Moulder, CEO, TESARO
Michael Yu, President and CEO, Innovent Biologics
Li Chen, CEO and Co-Founder, Hua Medicine
Mike Ward, Global Director of Content, Informa Pharma Insight
VP of Corporate Alliances and Head of Communications, WuXi AppTec
President and CEO, California Life Sciences Association
Founder, Chairman and CEO, WuXi AppTec
President and CEO, BioCentury
CEO, Denali Therapeutics
CEO, Unity Biotechnology
Co-Founder and CEO, IDEAYA Biosciences
New Paradigms in Creating Extraordinary Companies
CFO and CIO, WuXi AppTec
Partner, Third Rock Ventures
Professor at Stanford University; Chairman, Danhua Capital
Joint Head of Portfolio Strategy & Risk Group and Joint Head of China, Temasek
SPOTLIGHT: Are We Lost in Translation?
Erving Professor of Chemistry, Harvard University; CEO, FogPharma and LifeMine; Partner, WuXi Healthcare Ventures
Head of Pharma Research and Early Development (pRED), Roche
CEO, The Scripps Research Institute and Calibr
Prediction, Prevention, and Personalization: The New Name of the Game
Professor of Baylor College and SVP of Medical Science & Diagnostics, WuXi NextCODE
Chief Business Officer, GRAIL
Chair, Department of Laboratory Medicine and Pathology, Mayo Clinic; President, Mayo Medical Laboratories
President and CEO, Adaptive Biotechnologies
Better and Faster: How to do it?
EVP and COO, WuXi AppTec
President and CEO, Innovent Biologics
CEO and Co-Founder, Hua Medicine
Global Director of Content, Informa Pharma Insight
Brought to you by:
WuXi Global Forum 2017 Recap: